In 1999, NICE was set up to end the postcode lottery in access to medicines across the country – now healthtech is getting ...

Pre-exposure prophylaxis (PrEP) is a daily pill taken by HIV-negative people to prevent HIV infection. It can also be taken on demand before and after sex. The medicine stops the virus from getting ...

NICE has recommended a standardised approach for rehabilitation, to address the variation of care experienced by millions of people with chronic neurological conditions. In a new guideline published ...

Our initiative centres on closer collaboration and information sharing between NICE and MHRA to enable parallel publication of decisions on licensing and value. The impact of this will be significant ...

May 2022: This guideline has been withdrawn because current practice is to manage COVID-19 risk in line with risk of other respiratory infections. See our guidance on treating severe asthma and our ...

This quality standard covers assessment, early management and rehabilitation following head injury in adults, young people and children. It describes high-quality care in priority areas for ...

This guideline covers diagnosing and managing non-small-cell and small-cell lung cancer. It aims to improve outcomes for patients by ensuring that the most effective tests and treatments are used, and ...

All NICE products on oesophageal cancer. Includes any guidance and quality standards.

Suggested remit: To appraise the clinical and cost effectiveness of belantamab mafodotin within its marketing authorisation for treating relapsed or refractory multiple myeloma after 4 or more ...

Off-pump minimal access mitral valve repair by artificial chordae insertion to treat mitral regurgitation Interventional procedure consultation Interventional procedures guidance 28 October 2025 ...

Olaparib for maintenance treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based ...

Suggested remit: To appraise the clinical and cost effectiveness of lecanemab within its marketing authorisation for treating mild cognitive impairment or mild dementia caused by Alzheimer’s disease.